Drug Trial Radar · NCT00540449
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
Last checked: Nov 20, 2026Latest source record: Mar 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
694
Actual
Start
May 2008
Primary completion
Feb 2010
Study completion Dec 2011
Sponsor
- Lead sponsor
- Tibotec Pharmaceuticals, IrelandIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen consisting of emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF), in HIV-1 infected patients who have not yet taken any anti-HIV drugs. The following evaluations will be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution, relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics, medical resource utilization and treatment adherence.
Conditions
- HIV Infections
- HIV-1
- Human Immunodeficiency Virus Type 1
Interventions
TMC278Drug
25 mg tablet once daily for 96 weeks
EfavirenzDrug
600mg once daily for 96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48Time frame: Week 48
Locations
92 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Sacramento, California
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Vero Beach, Florida
Site not named
West Palm Beach, Florida
Site not named
Macon, Georgia
Site not named
Chicago, Illinois
Site not named
Baltimore, Maryland
Site not named
Newark, New Jersey
Site not named
Albany, New York
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Columbia, South Carolina
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Seattle, Washington
Site not named
Milwaukee, Wisconsin
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Guernica, Argentina
Site not named
Darlinghurst, Australia
Site not named
Melbourne, Australia
Site not named
Perth, Australia
Site not named
Surry Hills, Australia
Site not named
Innsbruck, Austria
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.